355836-05-4Relevant academic research and scientific papers
Discovery of N -(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4- trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): An orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
Hodgetts, Kevin J.,Ge, Ping,Yoon, Taeyoung,Lombaert, Stéphane De,Brodbeck, Robbin,Gulianello, Michael,Kieltyka, Andrzej,Horvath, Raymond F.,Kehne, John H.,Krause, James E.,Maynard, George D.,Hoffman, Diane,Lee, Younglim,Fung, Laurence,Doller, Dario
, p. 4187 - 4206 (2011/08/21)
The design, synthesis, and structure-activity relationships of a novel series of pyrazines, acting as corticotropin releasing factor-1 (CRF-1) receptor antagonists, are described. Synthetic methodologies were developed to prepare a number of substituted p
SUBSTITUTED ARYLPYRAZINES
-
, (2008/06/13)
Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
